{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T02:34:21Z","timestamp":1770518061274,"version":"3.49.0"},"reference-count":39,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2018,7,3]]},"DOI":"10.1080\/14787210.2018.1489721","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T12:09:41Z","timestamp":1529323781000},"page":"523-530","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":29,"title":["Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant <i>Staphylococcus aureus<\/i> (MRSA) and <i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1080","volume":"16","author":[{"given":"Eric R.","family":"Ocheretyaner","sequence":"first","affiliation":[{"name":"Division of Pharmacy Practice, LIU Pharmacy (Arnold & Marie Schwartz College of Pharmacy and Health Sciences), Brooklyn, NY, USA"},{"name":"Department of Pharmacy, Kings County Hospital Center, Brooklyn, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Eun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, BronxCare Health System, Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.39"},{"key":"CIT0002","unstructured":"Centers for Disease Control and Prevention (CDC). About Antimicrobial Resistance. https:\/\/www.cdc.gov\/drugresistance\/about.html. Last updated April 6, 2017."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-016-0150-4"},{"key":"CIT0004","volume-title":"Baxdela\u00ae (delafloxacin) [package insert] Lincolnshire","year":"2017"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S106071"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-10"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00772-17"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02609-16"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00941-16"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02798-15"},{"key":"CIT0011","volume-title":"M100 \u2013 26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"CIT0012","unstructured":"EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters, version 6.0, January. http:\/\/www\/eucast.org\/clinical_breakpoints\/. Accessed December 6, 2017."},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.817"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.11.019"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.10.016"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.04.009"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.10.009"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv411"},{"key":"CIT0019","doi-asserted-by":"crossref","unstructured":"Cammarata S, Gardovskis J, Farley B, et al. Results of a global phase 3 study of delafloxacin (DLX) compared to vancomycin with aztreonam (VAN) in acute bacterial skin and skin structure infections (ABSSSI). Abstract presented at: ID Week Meeting; October 7\u201311, 2015; San Diego, CA.","DOI":"10.1093\/ofid\/ofv133.493"},{"key":"CIT0020","unstructured":"O\u2019Riordan W, McManus A, Teras J, et al. A global phase 3 study of delafloxacin (DLX) compared to vancomycin\/aztreonam (VAN\/AZ) in patients with acute bacterial skin and skin structure infections (ABSSSI). Abstract presented at: ID Week Meeting; October 26\u201330, 2016; New Orleans, LA."},{"key":"CIT0021","unstructured":"Melinta Therapeutics, Inc. The Antibiotics Company. Baxdela (Delafloxacin): United States. http:\/\/melinta.com\/pipeline\/baxdela\/. Accessed December 28 2017."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx329"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04813-14"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.02.023"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw709"},{"key":"CIT0026","unstructured":"U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm500143.htm. Last updated October 12, 2017."},{"key":"CIT0027","volume-title":"Levaquin\u00ae (levofloxacin) [package insert] Lake Forest, IL: Hospira, Inc"},{"key":"CIT0028","unstructured":"Melinta Therapeutics. Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin\u2019s Potent in-vitro Activity Against Complicated Urinary Tract Infection Pathogens. http:\/\/melinta.com\/melinta-therapeutics-and-hartford-hospital-demonstrate-delafloxacins-potent-in-vitro-activity-against-complicated-urinary-tract-infection-pathogens\/. Accessed January 1, 2018."},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01374-09"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.06.006"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00832-10"},{"key":"CIT0032","volume-title":"Proceedings of the 48th interscience conference of antimicrobial agents and chemotherapy","author":"Buissonniere A","year":"2008"},{"key":"CIT0033","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1128\/AAC.00078-09","volume":"53","author":"Adam HJ, Laing NM, King CR, et al","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0034","first-page":"1923","volume":"64","author":"Barry AL","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp370"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01407-05"},{"key":"CIT0037","unstructured":"Centers for Disease Control and Prevention (CDC). Antibiotic-Resistant Gonorrhea. https:\/\/www.cdc.gov\/std\/gonorrhea\/arg\/default.htm. Last updated December 6, 2017."},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"CIT0039","unstructured":"Melinta Therapeutics. Melinta Therapeutics Ceases Phase 3 PROCEEDING Study. http:\/\/melinta.com\/melinta-therapeutics-ceases-phase-3-proceeding-study\/. Accessed January 1, 2018."}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2018.1489721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T19:25:58Z","timestamp":1599420358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2018.1489721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7,3]]}},"alternative-id":["10.1080\/14787210.2018.1489721"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2018.1489721","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}